MA31780B1 - Anticorps anti-glypican-3 dont la cinétique dans le plasma est améliorée - Google Patents

Anticorps anti-glypican-3 dont la cinétique dans le plasma est améliorée

Info

Publication number
MA31780B1
MA31780B1 MA32777A MA32777A MA31780B1 MA 31780 B1 MA31780 B1 MA 31780B1 MA 32777 A MA32777 A MA 32777A MA 32777 A MA32777 A MA 32777A MA 31780 B1 MA31780 B1 MA 31780B1
Authority
MA
Morocco
Prior art keywords
glypican
plasma
antibody
enhanced
life
Prior art date
Application number
MA32777A
Other languages
Arabic (ar)
English (en)
Inventor
Tomoyuki Igawa
Taichi Kuramochi
Hirotake Shiraiwa
Hiroyuki Tsunoda
Tatsuhiko Tachibana
Takahiro Ishiguro
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40510966&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31780(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA31780B1 publication Critical patent/MA31780B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de régulation de la demi-vie d'un anticorps anti-glypican-3 dans le plasma, une composition pharmaceutique comprenant, comme ingrédient actif, un anticorps anti-glypican-3 dont la demi-vie dans le plasma est régulée, un procédé de production de l'anticorps anti-glypican-3, et un procédé de production d'une composition pharmaceutique comprenant, comme ingrédient actif, l'anticorps anti-glypican-3. Elle concerne un procédé de régulation de la demi-vie d'un anticorps anti-glypican-3 dans le plasma par modification d'un résidu d'acide aminé exposé à la surface de l'anticorps anti-glypican-3, un anticorps anti-glypican-3 dont la demi-vie dans le plasma est régulée par modification d'un résidu d'acide aminé, une composition pharmaceutique comprenant l'anticorps comme ingrédient actif, et un procédé de production de la composition pharmaceutique.
MA32777A 2007-09-28 2010-04-14 Anticorps anti-glypican-3 dont la cinétique dans le plasma est améliorée MA31780B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007256063 2007-09-28
PCT/JP2008/002690 WO2009041062A1 (fr) 2007-09-28 2008-09-26 Anticorps anti-glypican-3 dont la cinétique dans le plasma est améliorée

Publications (1)

Publication Number Publication Date
MA31780B1 true MA31780B1 (fr) 2010-10-01

Family

ID=40510966

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32777A MA31780B1 (fr) 2007-09-28 2010-04-14 Anticorps anti-glypican-3 dont la cinétique dans le plasma est améliorée

Country Status (26)

Country Link
US (3) US8497355B2 (fr)
EP (3) EP2584043A3 (fr)
JP (3) JP4535406B2 (fr)
KR (2) KR20100085067A (fr)
CN (1) CN101809162B (fr)
AR (1) AR066172A1 (fr)
AU (1) AU2008305851B2 (fr)
BR (1) BRPI0817637A2 (fr)
CA (1) CA2700986A1 (fr)
CL (1) CL2008002873A1 (fr)
CO (1) CO6270266A2 (fr)
CR (1) CR11369A (fr)
DK (1) DK2196541T3 (fr)
EC (1) ECSP10010135A (fr)
ES (1) ES2394471T3 (fr)
HK (1) HK1144702A1 (fr)
IL (1) IL204754A0 (fr)
MA (1) MA31780B1 (fr)
MX (1) MX2010003158A (fr)
MY (1) MY148637A (fr)
NZ (1) NZ584769A (fr)
PE (1) PE20091218A1 (fr)
RU (2) RU2445366C2 (fr)
TW (1) TWI418363B (fr)
WO (1) WO2009041062A1 (fr)
ZA (1) ZA201002741B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5620626B2 (ja) * 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
EP4001409A1 (fr) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Procédés pour le contrôle de la pharmacocinétique sanguine d'anticorps
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
KR102467302B1 (ko) 2007-09-26 2022-11-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
MY177564A (en) 2007-12-05 2020-09-20 Chugai Pharmaceutical Co Ltd Anti-nr10 antibody and use thereof
US8124725B2 (en) 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
US8937047B2 (en) * 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
EP3521311A1 (fr) * 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Molécule se liant à des antigènes capable de se lier à deux ou plusieurs molécules d'antigène de manière répétée
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
RU2011151069A (ru) 2009-05-15 2013-06-20 Чугаи Сейяку Кабусики Кайся Анти-axl антитело
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2543730B1 (fr) * 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante de région constante d'anticorps
BR112012022917A2 (pt) * 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
US8637641B2 (en) * 2010-07-29 2014-01-28 Xencor, Inc. Antibodies with modified isoelectric points
US9334331B2 (en) 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
CA2819356C (fr) * 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Molecule de liaison a l'antigene, apte a se lier de facon repetee a une pluralite de molecules d'antigene
WO2012132067A1 (fr) * 2011-03-30 2012-10-04 中外製薬株式会社 Rétention de molécules de liaison d'antigène dans le plasma sanguin et procédé pour modifier l'immunogénicité
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
DK2698431T3 (da) 2011-03-30 2020-11-30 Chugai Pharmaceutical Co Ltd Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
KR20240027154A (ko) * 2011-03-30 2024-02-29 추가이 세이야쿠 가부시키가이샤 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법
EP2728002B1 (fr) 2011-06-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Polypeptide hétérodimérisé
WO2013047748A1 (fr) 2011-09-30 2013-04-04 中外製薬株式会社 Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3778889A1 (fr) 2011-09-30 2021-02-17 Chugai Seiyaku Kabushiki Kaisha Bibliothèque de molécules de liaison dépendant de la concentration ionique
CA2857159C (fr) * 2011-11-30 2024-05-07 Chugai Seiyaku Kabushiki Kaisha Support contenant des medicaments dans une cellule pour former un complexe immunitaire
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
SG11201407972RA (en) * 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2013187495A1 (fr) 2012-06-14 2013-12-19 中外製薬株式会社 MOLÉCULE DE LIAISON À L'ANTIGÈNE CONTENANT UNE RÉGION Fc MODIFIÉE
EP3495387B1 (fr) 2012-07-13 2021-09-01 Roche Glycart AG Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le traitement des maladies vasculaires oculaires
KR20230110836A (ko) 2012-08-24 2023-07-25 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체
EP4119947A1 (fr) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Médicament de ciblage gpc3 administré à un patient en réponse à une thérapie médicamenteuse de ciblage gpc3
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
DK2940135T5 (da) 2012-12-27 2021-09-20 Chugai Pharmaceutical Co Ltd Heterodimeriseret polypeptid
EP2982689B1 (fr) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Variant de région fc
KR20160022354A (ko) 2013-06-24 2016-02-29 추가이 세이야쿠 가부시키가이샤 인간화 항에피레귤린 항체를 유효성분으로서 포함하는 선암 이외의 비소세포폐암의 치료제
RU2758952C1 (ru) 2013-09-27 2021-11-03 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
CA2924448C (fr) * 2013-11-29 2021-12-14 Genentech, Inc. Appareil et procedes de selection d'anticorps
CN106459959A (zh) 2014-05-08 2017-02-22 中外制药株式会社 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂
US9926377B2 (en) 2014-05-22 2018-03-27 Genentech, Inc. Anti-GPC3 antibodies and immunoconjugates
JP2017522861A (ja) * 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
WO2016036973A1 (fr) * 2014-09-04 2016-03-10 The Trustees Of The University Of Pennsylvania Anticorps anti-glypican-3 et ses utilisations
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI758928B (zh) * 2014-11-21 2022-03-21 美商必治妥美雅史谷比公司 抗cd73抗體及其用途
WO2016085787A1 (fr) 2014-11-25 2016-06-02 Corning Incorporated Matériaux et procédés d'extension de milieux de culture cellulaire
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
ES2899894T3 (es) 2014-12-19 2022-03-15 Chugai Pharmaceutical Co Ltd Anticuerpos anti-C5 y métodos de uso
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
BR112017014067B1 (pt) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
KR20180091918A (ko) 2015-12-28 2018-08-16 추가이 세이야쿠 가부시키가이샤 Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
WO2017159699A1 (fr) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Procédés de traitement de cancers au moyen d'antagonistes se liant à l'axe pd-1 et d'anticorps anti-gpc3
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
JP7125347B2 (ja) 2016-08-22 2022-08-24 中外製薬株式会社 ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
CA3045466A1 (fr) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Anticorps anti-pd-l1 radiomarques pour imagerie immuno-pet
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
JPWO2018155611A1 (ja) 2017-02-24 2019-12-12 中外製薬株式会社 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
WO2018203545A1 (fr) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
US20200216542A1 (en) 2017-09-20 2020-07-09 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
WO2021236546A1 (fr) * 2020-05-18 2021-11-25 Bristol-Myers Squibb Company Variants d'anticorps ayant des propriétés pharmacocinétiques améliorées
CN116194473A (zh) 2020-07-28 2023-05-30 中外制药株式会社 包含新改造型抗体的具备针护罩的带针预充注射器制剂
WO2023030539A1 (fr) * 2021-09-06 2023-03-09 Nanjing Legend Biotech Co., Ltd. Récepteur antigénique chimérique anti-gpc3 et ses procédés d'utilisation
CA3237201A1 (fr) 2021-11-16 2023-05-25 Sotio Biotech Inc. Traitement de patients atteints de liposarcome myxoide/a cellules rondes
WO2024011186A2 (fr) * 2022-07-08 2024-01-11 Imaginab, Inc. Anticorps, leurs procédés de fabrication et leurs méthodes d'utilisation
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS6459878A (en) 1987-08-31 1989-03-07 Matsushita Electric Ind Co Ltd Semiconductor laser protective circuit
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
EP0605522B1 (fr) 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
WO1993011236A1 (fr) 1991-12-02 1993-06-10 Medical Research Council Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage
EP0656941B1 (fr) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Procedes de production d'elements de paires de liaison specifiques
WO1994002602A1 (fr) 1992-07-24 1994-02-03 Cell Genesys, Inc. Production d'anticorps xenogeniques
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (fr) 1993-12-03 1996-09-18 Medical Research Council Proteines et peptides de liaison recombines
US6214613B1 (en) 1993-12-03 2001-04-10 Ashai Kasei Kogyo Kabushiki Kaisha Expression screening vector
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
ZA976326B (en) * 1996-07-19 1998-02-03 Amgen Inc Analogs of cationic proteins.
CZ106299A3 (cs) 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
EP1020522B1 (fr) 1997-10-03 2007-09-19 Chugai Seiyaku Kabushiki Kaisha Anticorps humain naturel
ES2420835T3 (es) * 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
DE60228721D1 (en) 2001-06-22 2008-10-16 Chugai Pharmaceutical Co Ltd Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
WO2004023145A1 (fr) * 2002-09-04 2004-03-18 Perseus Proteomics Inc. Procede de detection du cancer par detection du gpc3
EP1553975B8 (fr) * 2002-09-27 2023-04-12 Xencor, Inc. Variants fc optimises et methodes destinees a leur generation
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1562972B1 (fr) 2002-10-15 2010-09-08 Facet Biotech Corporation MODIFICATION D'AFFINITES DE LIAISON POUR FcRn OU DE DEMI-VIES SERIQUES D'ANTICORPS PAR MUTAGENESE
JP2008501677A (ja) 2004-06-04 2008-01-24 ファイザー・プロダクツ・インク 異常な細胞増殖を治療する方法
DE102004032634A1 (de) * 2004-07-06 2006-02-16 Sms Demag Ag Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
ATE486610T1 (de) * 2004-07-09 2010-11-15 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
PT1800693E (pt) 2004-08-24 2013-08-23 Chugai Pharmaceutical Co Ltd Terapia adjuvante utilizando anticorpo antiglipicana
JP4455236B2 (ja) * 2004-09-02 2010-04-21 本田技研工業株式会社 芝刈機
CN101068836B (zh) 2004-10-26 2013-08-14 中外制药株式会社 糖链改变的抗磷脂酰肌醇聚糖3抗体
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
EP1899477A4 (fr) * 2005-07-01 2010-01-20 Medimmune Inc Approche integree permettant de generer des applications therapeutiques a base de proteine multidomaine
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007053573A2 (fr) 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Traitement du cancer au moyen de sorafenib
WO2007059111A2 (fr) * 2005-11-14 2007-05-24 Entremed, Inc. Activite antiangiogenese du 2-methoxyestradiol en combinaison avec des agents anticancereux
BRPI0619056A2 (pt) * 2005-11-28 2011-09-20 Genmab As anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica
CN101415422B (zh) 2006-02-09 2012-11-07 第一三共株式会社 抗癌药用组合物
WO2007099988A1 (fr) 2006-02-28 2007-09-07 Kyowa Hakko Kogyo Co., Ltd. mutant de α-1,6-FUCOSYLTRANSFERASE et son utilisation
JP2007256063A (ja) 2006-03-23 2007-10-04 Seiko Epson Corp 表示装置、および、電子機器
EP4001409A1 (fr) * 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Procédés pour le contrôle de la pharmacocinétique sanguine d'anticorps
US9670269B2 (en) * 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
WO2007137170A2 (fr) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Conjugués médicamenteux d'anticorps anti-glypicane-3
PT2178921E (pt) * 2007-07-17 2016-03-23 Squibb & Sons Llc Anticorpos monoclonais contra glipicano-3
DK2202245T3 (en) * 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.

Also Published As

Publication number Publication date
HK1144702A1 (en) 2011-03-04
NZ584769A (en) 2011-09-30
JP4535406B2 (ja) 2010-09-01
KR20100085067A (ko) 2010-07-28
EP2196541B1 (fr) 2012-11-07
JP2010200768A (ja) 2010-09-16
AU2008305851A1 (en) 2009-04-02
TW200930406A (en) 2009-07-16
ES2394471T3 (es) 2013-02-01
CA2700986A1 (fr) 2009-04-02
EP2196541A4 (fr) 2010-11-03
AR066172A1 (es) 2009-07-29
US8497355B2 (en) 2013-07-30
EP2584043A2 (fr) 2013-04-24
WO2009041062A1 (fr) 2009-04-02
RU2010116756A (ru) 2011-11-10
AU2008305851B2 (en) 2014-12-18
CN101809162A (zh) 2010-08-18
IL204754A0 (en) 2010-11-30
CO6270266A2 (es) 2011-04-20
BRPI0817637A2 (pt) 2015-09-08
DK2196541T3 (da) 2012-11-26
EP2617736A1 (fr) 2013-07-24
CN101809162B (zh) 2013-06-05
JP2014005292A (ja) 2014-01-16
JP5382873B2 (ja) 2014-01-08
EP2196541A1 (fr) 2010-06-16
KR20150126724A (ko) 2015-11-12
US20150315278A1 (en) 2015-11-05
US20100239577A1 (en) 2010-09-23
CR11369A (es) 2010-08-12
PE20091218A1 (es) 2009-08-14
RU2010125605A (ru) 2011-12-20
MY148637A (en) 2013-05-15
ECSP10010135A (es) 2010-07-30
TWI418363B (zh) 2013-12-11
RU2445366C2 (ru) 2012-03-20
ZA201002741B (en) 2011-10-26
MX2010003158A (es) 2010-04-14
JP6101611B2 (ja) 2017-03-22
EP2584043A3 (fr) 2013-10-02
CL2008002873A1 (es) 2010-02-19
JPWO2009041062A1 (ja) 2011-01-20
US20130295612A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
MA31780B1 (fr) Anticorps anti-glypican-3 dont la cinétique dans le plasma est améliorée
MX369784B (es) Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
MA31984B1 (fr) Formulation d'anticorps
MA34837B1 (fr) Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
MA29171B1 (fr) Formulation a compression directe et procede associe
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA31797B1 (fr) Compositions pharmaceutiques
MA35341B1 (fr) Compositions pesticides et procedes relatifs a ces compositions
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
MA30975B1 (fr) Formulation parenterale d'anticorps anti-peptide abeta
MX2011004324A (es) Proceso novedoso para la preparacion de derivados de aminoacidos.
NZ605873A (en) Methods and compositions for cns delivery of arylsulfatase a
MA38330B1 (fr) Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
TW200833682A (en) Pharmaceutical compounds
WO2003099338A3 (fr) Conjugues d'acides amines permettant d'obtenir des concentrations systemiques prolongees d'analogues gaba
MA27670A1 (fr) Composition pharmaceutique contenant de l'acide 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetique
MA33676B1 (fr) Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée
MA37317B1 (fr) Formulation d'anticorps il-17
HK1111168A1 (en) A PROCESS FOR THE PREPARATION OF 17-HYDROXY-6 ß,7ß,15 ß,16 ß - BISMETHYLENE-17a-PREGN-4-ENE-3-ONE-21-CARBOXYLIC ACID Y-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS
MA38646B1 (fr) Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa.
MY151183A (en) Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof
Amankwa et al. Novel thiol containing hybrid antioxidant-nitric oxide donor small molecules for treatment of glaucoma
TW200745155A (en) Preparation of pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl)betulinic acid
BR0309298A (pt) Método para estabilizar comprimidos de cloreto de bupropion